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Macrophage migration inhibitory factor (MIF), an inﬂammatory cytokine, and its receptor CD74 are upregulated by bladder
inﬂammation. MIF-mediated signal transduction involves binding to cell-surface CD74, this study documents, in vivo, MIF-
CD74 interactions at the urothelial cell surface. N-hydroxysulfosuccinimide biotin ester-labeled surface urothelial proteins in
rats treated either with saline or substance P (SP, 40μg/kg). The bladder was examined by histology and confocal microscopy.
Biotinylated proteins were puriﬁed by avidin agarose, immunoprecipitated with anti-MIF or anti-CD74 antibodies, and detected
with strepavidin-HRP. Only superﬁcial urothelial cells were biotinylated. These cells contained a biotinylated MIF/CD74 cell-
surface complex that was increased in SP-treated animals. SP treatment increased MIF and CD74 mRNA in urothelial cells. Our
data indicate that intraluminal MIF, released from urothelial cells as a consequence of SP treatment, interacts with urothelial cell-
surface CD74. These results document that our previously described MIF-CD74 interaction occurs at the urothelial cell surface.
Copyright © 2009 Katherine L. Meyer-Siegler et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1.Introduction
The urothelium is no longer regarded as a passive barrier
but rather as a complex “sensory web” transducing signals
from inside the viscus (and in response to neuronal and
localchanges)throughtheactivationofcell-surfacereceptors
[1]. Therefore, the study of interactions between urothelial
cell-surface receptors expressed during normal and diseased
states and diﬀerent molecules is likely to shed light on
urothelial signal transduction in health and disease.
A central question in the study of tissue response to
inﬂammation is how cells titrate and integrate cytokine
signals in order to respond in an appropriate manner.
Regulation of the speciﬁc pathway through bioavailability
of ligands and/or receptors is one potential mechanism.
Receptor bioavailability is achieved predominantly through
the cell-surface expression of speciﬁc functional receptors.
Theligand-receptorinteractionresultsinthetransductionof
these extracellular signals across the plasma membrane and,
through the activation of intracellular signaling pathways,
aﬀect the appropriate functional response.
We have been studying the role of a unique proinﬂam-
matory cytokine, macrophage migration inhibitory factor
(MIF) in experimental and clinical cystitis [2–4]. MIF is
constitutively expressed and secreted by numerous cell types,
and signiﬁcant levels can be found in blood, urine, cere-
brospinal and other body ﬂuids [5, 6]. Therefore, circulating
or extracellular MIF is readily available, even under basal
(“normal”) conditions [7] .T h eu b i q u i t o u sn a t u r eo ft h i s
cytokine suggests that cellular response to MIF is dictated
either by increasing the amount of available MIF or by
changes in receptor bioavailability. We have demonstrated
that subcutaneous SP increases intraluminal MIF amounts,2 Mediators of Inﬂammation
which is localized in preformed urothelial stores [4]. In addi-
tion, sequestering intraluminal MIF with antibodies reduced
SP-induced inﬂammatory changes in the rat bladder [8].
Thus, increased intraluminal MIF participates in a feedback
loop that continues to maintain SP-induced inﬂammatory
changesinthebladder.TheprecisemechanismofMIFaction
is unknown. However, numerous studies have contributed to
the current consensus that the involvement of MIF is central
in the initiation of the inﬂammatory response [9, 10].
Using in vitro models, the MIF receptor was identiﬁed
as the cell-surface form of CD74 (also known as the
invariant chain) [11]. The primary function of CD74 is
to regulate peptide loading onto major histocompatibility
class II heterodimers [12]. However, a small portion of the
total cell CD74 content is expressed on cell surfaces, but
the exact function of cell-surface CD74 is not known [13].
Recent studies have documented the interaction of MIF
with CD74; however, it is not likely that this interaction
is suﬃcient to produce proinﬂammatory eﬀects without
the presence of CD44 (MIF-CD74 signaling component)
[11, 14]. MIF, CD74, and CD44 are all upregulated during
experimental bladder inﬂammation suggesting that MIF-
mediated signaling may be involved in cystitis [15, 16].
Generally, cell-surface expression of CD74 is rather low,
varying in monocytes from a few hundred to a few thousand
molecules per cell (for comparison, there are approx. 3 × 105
molecules of the MIF signal molecule CD44 per cell) again
suggesting that cell-surface availability of CD74 is the rate
limiting variable in MIF signal transduction [17].
We previously showed that additional MIF is released
from the bladder as part of the inﬂammatory response, and
is subsequently localized to umbrella cells in the urothelium
[18]. In addition, we showed increased amounts of CD74
protein localized to the urothelial layer suggesting that CD74
is a potential receptor for MIF-mediated signal transduction
during bladder inﬂammation [16]. Therefore, we hypoth-
esize that urothelial cell-surface CD74-MIF binding and
subsequent association with CD44 activates ERK1/2 signal
transduction pathways. Taken together, our previous results
suggest that the bioavailability of the CD74 rather than
MIF dictates cell response. Therefore, we examined the
cell-surface location and extents of CD74 and MIF-CD74
in urothelial cells and the eﬀects of bladder inﬂammation
induced by SP using in vivo biotinylation of cell-surface
proteins and confocal microscopy.
2. Methods
2.1. Animal Model. In vivo biotinylation of urothelial cell-
surface proteins—twelve male Sprague-Dawley rats (250–
300gm) were anesthetized with sodium pentobarbital
(60mg/kg; i.p.) and divided into two groups: (1) saline
(N = 6): bladders isolated from kidneys by cutting ureters;
bladders emptied of urine, rinsed twice with PBS, and
replaced with 0.3mL biotinylation reagent (1mg/mL N-
hydroxysulfosuccinimide biotin ester, Pierce Biochemicals,
Rockford, Ill, USA); saline treatment (s.c.); (2) substance P
( S P ,S i gm a ,S t .L o u i s ,M o ,U S A ;N = 6): bladders treated as in
group(1)withSPtreatment(40μg/kg;s.c.).After1hour,the
bladders were excised and cut in half. Half of the bladder was
placed in formalin for histology and confocal microscopy,
while the remaining piece was carefully stretched and
urothelial cells enriched using epithelial aggregate separation
and isolation (EASI) [19].
2.2. Histology. Biotinylation of bladder tissue was detected
by exposing frozen bladder sections (14μm thick; intact
bladders) to strepavidin- horseradish peroxidase (HRP)
conjugate and developing with 1% 3,3 -diaminobenzidine
tetrahydrochloride in 0.3% hydrogen peroxide (Sigma).
Frozen sections (14μm thick) of scraped bladders were
stained using hematoxylin to document that only the
epithelium was removed from the underlying tissue.
2.3. Puriﬁcation and Detection of Biotinylated Proteins.
Isolated urothelial cells were collected by centrifugation
at 10000g for 5 minutes, then washed in three times
with 100mM glycine in PBS pH 8.0 to inactivate residual
biotinylation reagent. Half of the collected urothelial cells
were processed for protein and the remaining used for RNA
isolation.
Proteins were extracted from isolated urothelial cells
by resuspension of washed cells in ice-cold RIPA buﬀer
(50mM Tris-HCL, pH 7.5, 150mM NaCl with 1% Triton
X-100, 0.1% SDS, and 0.25% sodium deoxycholate, plus
general protease inhibitors; Sigma), dounce homogenization
followed by centrifugation at 12000g for 15 minutes at 4◦C.
Protein concentrations in the cleared cell lysates were deter-
mined using the Micro-BCA protocol (Pierce Biochemicals,
Rockford, Ill, USA).
Urothelial cell lysates (10μg total protein) were separated
o n4 – 1 2 %b i st r i sa c r y l a m i d eg e l s( N u P A G E ,I n v i t r o g e n ,
Carlsbad, Calif, USA) and transferred to PVDF. Western-
blotting using antivimentin (ﬁbroblast marker, Neuromics,
Edina, Minn, USA; #CH23010) veriﬁed that only urothelial
cells were removed and isolated. Western blots were stripped
(0.2M glycine, pH 2.2 containing 0.1% SDS, 1% Tween-
20) and reprobed with GAPDH antibody (Santa Cruz
Biotechnology, Santa Cruz, Calif, USA; sc-20357), which
served as a loading control.
Urothelial surface proteins labeled with biotin were
puriﬁed from total urothelial cell proteins by avidin-agarose
aﬃnity chromatography (A1979, Sigma). Nonexchangeable
biotin binding sites were blocked by incubating 100μLo f
avidin-agarose resin with 400μLo fb i o t i n( 1 m g / m L )f o r
1 5m i n u t e sa tr o o mt e m p e r a t u r e .B i o t i nw a se l u t e df r o m
exchangeable binding sites by washing the resin three times
with 500μL 0.1M glycine, pH 2.0. The prepared resin was
equilibrated with PBS and incubated with 1mg of total
urothelial cell lysate. Biotinylated proteins were eluted with
2mM biotin and concentrated ﬁvefold through 0.2μmﬁ l -
ters. Avidin-puriﬁed proteins (15μL of ﬁvefold-concentrated
avidin-agarose eluate) isolated from each animal were
separated by SDS-PAGE (Invitrogen) and transferred to
PVDF. Blots were blocked in blocking buﬀer (1% BSA,
10mM PBS, pH 7.5. and 0.05% Tween-20) for 1 hour atMediators of Inﬂammation 3
37◦C and total biotinylated protein detected by incubating
for 1 hour at 37◦C with HRP-labeled strepavidin (1:200
dilution in blocking buﬀer R&D Systems, Minneapolis,
Minn, USA). The blot was then washed, and biotinylated
proteins visualized and quantiﬁed with a chemiluminescent
imaging system (substrate, Super Signal West Dura, Pierce;
Kodak Image Station, Kodak, Rochester, NY, USA). Total
band intensities were determined using the manufacturer
software (Kodak) and expressed in arbitrary units. Data are
expressed as median ± interquartile range.
2.4. Immunoprecipitation. Neither MIF nor CD74 could be
detected in the avidin-puriﬁed urothelial cell lysates using
standard Western blotting procedures, therefore immuno-
precipitation was used. Equal amounts of total protein form
the urothelial cell lysates (1mg, saline animals 4 and 5; SP
animals 9 and 10) were puriﬁed by avidin agarose, and the
resulting biotinylated proteins precleared by incubation with
protein A agarose beads for 1 hour at 4◦C. The precleared
biotinylated proteins were divided into two equal aliquots
and incubated overnight with 5μg of the corresponding
antibody (CD74, Santa Cruz Biotechnology, sc-5438; or
MIF, R&D Systems, AF-289-PB) at 4◦C. Protein A-agarose
beads (50% slurry) were added to the mixture, which was
incubated for 1 hour at 4◦C. Beads were then washed
three times in PBS and then resuspended in SDS sample
buﬀer. Controls included incubation of precleared samples
with nonspeciﬁc goat IgG (Sigma), GAPDH antibody (Santa
Cruz Biotechnology, sc-20357), or samples without the
addition of antibody in the immunoprecipitation reaction.
The resulting immunoprecipitated protein was separated by
4–12% Bis-Tris SDS-PAGE (Invitrogen) and transferred to
PVDF. Incubating the blot overnight with streptavidin-HRP
conjugate (R&D Systems, 1:200 dilution in blocking buﬀer,
no detection or secondary antibody was used) was used
to visualize only immunoprecipitated biotinylated protein.
Bands were visualized as described above.
2.5. Coimmunoprecipitation. Cell-surface MIF-CD74 com-
plexes were isolated by incubating avidin-agarose puriﬁed
biotinylated proteins (puriﬁed from 1mg total urothelial
lysate) with MIF antibody (R&D Systems, 1:1000 dilution,
saline animals 1, 2, 3, and 6; SP animals 7, 8, 11, and 12) at
4◦C overnight. Immunoprecipitated proteins were separated
as described above, and CD74 containing MIF complexes
were detected by overnight incubation with anti-CD74
antibody(SantaCruzBiotechnology,sc-5438)followedbyan
antigoat HRP conjugate (Pierce) and visualized as described
above.
2.6. PCR. Urothelial cell total RNA was isolated using TriZol
reagent (Invitrogen) with 1μg of RNA reverse transcribed
and the resulting cDNA (2μL) used for relative quantitative
PCR. Relative quantitative PCR conditions for MIF and
CD74 were established by determining the linear range of
the target. Conditions for the 18S rRNA primer/competimer
ratio were determined as described by the manufacturer
(3:7 primer:competimer ratio, Ambion, Austin, Tex, USA).
These primer rations optimized PCR conditions allow the
generated 18S rRNA product to be used as an internal
standard to correctforvariation in theinitial amount of total
RNA reverse transcribed, as well as tube-to-tube variations
inherent in the PCR reaction. MIF and CD74 were ampliﬁed
along with the 18S rRNA internal standard using high
stringency conditions: 30 cycles of 94◦C1m i n u t e ,6 3 ◦C1
minute, 72◦C 1 minute as described previously [20]. PCR-
generated fragments were separated on precast 2% agarose
gels containing ethidium bromide (E-Gel, Invitrogen) and
band intensity determined (Kodak, Rochester, NY, USA).
Relative band intensities were calculated by dividing total
gene of interest band intensity by 18S rRNA band intensity
(internal standard), and fold change in expression was
determined by dividing SP-treated relative band intensity by
mean saline (control) relative band intensity. Data represent
the mean ± SEM of two separate PCR reactions per
experimental animal. Reaction without reverse transcriptase
served as a negative control.
2.7. Confocal Microscopy. Frozen bladder sections (14μm;
intact bladders) were exposed to CD74 antiserum (sc-5438,
speciﬁc for extracellular domain, Santa Cruz Biotechnology)
and visualized using secondary antiserum labeled with FITC
or TRITC. Control experiments included omission of the
primary antiserum.
Confocal microscopy for cell-surface CD74 was perfo-
rmedwithaZeissLSM510laserscanningmicroscope(Thor-
nwood,NY,USA)withArgonlaser(forexcitationat488nm)
and HeNe1 laser (for excitation at 543nm). The slide was
mounted on a Zeiss-inverted microscope (Axiovert 100M)
with either Plan-Neoﬂuar 40×/0.75 N.A. air objective or
Plan-Apochromat 100×/1.4 N.A. oil objective. For each gro-
up of experiments, identical settings for the imaging collec-
tion were used (via Reuse function). All the confocal imag-
es were collected and analyzed using Zeiss software either
provided with the confocal imaging system or downloa-
ded from Zeiss website (AxioVision LE, http://www.zeiss
.com/C12567BE0045ACF1/Contents-Frame/3F3821B370EF
C91CC125734C002FB38C).
3. Results
3.1. In Vivo Biotinylation of Urothelial Cell Surface Proteins.
We developed a methodology to identify cell-surface protein
expression in the urothelium using in vivo biotinylation
and also determined urothelial cell-surface protein changes
induced by SP treatment. In both treatment and control
bladders, the biotinylation reaction occurred exclusively
at the umbrella cell layer (Figures 1(a)–1(d)) indicating
that only luminal cell-surface proteins were labeled with
biotin.BladderpiecesremainingfollowingEASIwerestained
with hematoxylin (Figures 2(a)–2(d)). As seen in both
treatment and control bladders, our procedures resulted
in the collection of only urothelial cells with the lamina
propria and smooth muscle tissue in the bladder remaining
intact (Figures 2(a)–2(d)). In addition, Western blotting of
urothelial lysates for vimentin (ﬁbroblast marker) from all4 Mediators of Inﬂammation
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Figure 1: In vivo biotinylation of urothelium. (a) and (c) saline-
treated bladders, (b) and (d) SP-treated bladders. Biotin labeling is
determined only with strepavidin-HRP and is localized to surface
urothelium. Calibration bar—(a), (b) = 400μm; (c), (d) = 100μm.
twelve animals was negative, while present in the remaining
(scraped) bladder pieces (Figures 2(e)), indicating that
lamina propia ﬁbroblasts were not included in the isolated
cells. Therefore, these results suggest that our procedures
successfully isolated urothelial cells without contamination
(as determined by histology and vimentin Western blotting)
from other cells in the lamina propia.
3.2. SP-Induced Changes in Urothelial Cell-Surface CD74
and MIF. Biotinylated proteins from isolated urothelial cells
were puriﬁed by avidin agarose and 15μL of the ﬁvefold
concentrated eluate separated by reducing SDS-PAGE. The
total amount of cell-surface biotinylated protein from each
was quantiﬁed by determining total band intensity in each
lane. Cell-surface protein as measured by biotinylated band
intensity increased tenfold (P = .002, Mann-Whitney) fol-
lowing SP treatment (lanes 7–12, Figure 3(a); total intensity
68340 ± 23710 arbitrary units) compared with control
animals (lanes 1–6, Figure 3(a); total intensity 6600 ± 2725
arbitrary units).
CD74 and MIF bands could not be detected by West-
ern blotting of equal aliquots of avidin-puriﬁed urothelial
cell lysates (data not shown), suggesting that the protein
concentration was below the detection limit of this assay.
Therefore, to test the relationship between relative amounts
of cell surface MIF/CD74 and SP treatment, avidin-puriﬁed
biotinylated proteins from urothelial lysates were immuno-
precipitated with MIF or CD74 antibodies and detected
using HRP-labeled strepavidin. SP treatment increased the
amount of cell-surface CD74 as evidenced by increased
amount of immunoprecipitable biotinylated CD74 from
SP-treated urothelial cells (P = .03, Mann-Whitney; right
panel, lanes 1, 2, animals 4, 5; lanes 3, 4, animals 9,
SAL
(a) (b)
SP
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123456
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78 91 0 1 1 1 2S
Vimentin
GADPH
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Figure 2: Epithelial aggregate separation and isolation (EASI) of
rat bladder urothelium. Hematoxylin staining of scraped bladders.
(a) and (b) saline-treated bladders, (c) and (d) SP-treated bladders.
EASI only removes urothelium leaving intact lamina propria.
Calibration bar—(a), (c) = 400μm; (b), (d) = 100μm. (e) Vimentin
Western blot of total urothelial cell lysates. Total protein from
isolated urothelial cells was separated on 4–12% bis tris acrylamide
gels and transferred to PVDF. Lanes 1–6 saline-treated animals;
lanes 7–12SP-treated animals, lane S—10μgo fs c r a p p e db l a d d e r
protein (positive control). Vimentin Western blot was stripped and
reprobed with GAPDH which served as a loading control.
10; Figure 3(b)). In addition, the amount of cell surface
(biotinylated) immunoprecipitable MIF was increased with
SP treatment (P = .03, Mann-Whitney; left panel, lanes
1, 2, animals 4, 5; lanes 3, 4, animals 9, 10; Figure 3(b)).
Not all the MIF was complexed to the 76kDa band since
12kDa MIF was found in the MIF immunoprecipitationMediators of Inﬂammation 5
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Figure 3: Expression of CD74 and MIF on urothelial bladder surface. (a) Total biotinylated protein. Isolated urothelial cells were lysed,
biotinylated proteins were isolated by avidin agarose aﬃnity chromatography, separated by 4–12% bis tris acrylamide gels electrophoresis,
transferred to PVDF and biotin containing protein bands visualized with strepavidin-HRP only, no antibodies were used. P: indicates
precipitation of proteins with avidin agarose, D: indicates detection with SA-HRP only, no antibodies were used. Lanes 1–6, saline-
treated animals; lanes 7–12 SP-treated animals. (b) Immunoprecipitation of biotinylated CD74 or MIF. Isolated urothelial cells were
lysed, 1mg of total biotinylated proteins was isolated by avidin agarose aﬃnity chromatography and biotinylated CD74 or MIF protein
was immunoprecipitated using appropriate antibodies. Precipitates were separated by denaturing-reducing SDS PAGE and CD74 or MIF
protein detected by strepavidin-HRP. P: indicates precipitation of proteins with MIF antibody (left panel) or CD74 antibody (right panel).
D: indicates detection with SA-HRP only (left and right panel), no antibodies were used. Lanes 1, 2 saline-treated animals (number 4
and 5 from Figure 3(a)), lanes 3, 4 SP-treated animals (numbers 9 and 10 from Figure 3(a)). G: indicates immunoprecipitation with
GAPDH antibody documents that only biotinylated proteins were immunoprecipitated, N: indicates immunoprecipitation with nonspeciﬁc
goat IgG documents antibody speciﬁcity. Lines and numbers to the far left indicate the position of molecular weight markers. Asterisk
indicates the location of 76kDa band. Arrow indicates the location of 12 kDa uncomplexed MIF. (c) Coimmunoprecipitation of cell-surface
MIF/CD74 complexes. Isolated urothelial cells were lysed, 1mg total protein was used to purify biotinylated proteins by avidin agarose
aﬃnity chromatography. Biotinylated MIF proteins were precipitated with an anti-MIF antibody. Precipitates were separated by denaturing-
reducing SDS PAGE and CD74 protein containing bands identiﬁed using anti-CD74 antibody followed by an antigoat-HRP. P: indicates
precipitation of proteins by MIF antibody. D: indicates detection with CD74 primary antibody and antigoat HRP secondary antibody.
Upper panel saline-treated animals, Lanes 1, 2, 3, 4, (numbers 1, 2, 3, and 6 from Figure 3(a)). Lower panel SP-treated animals, Lanes 1, 2, 3,
4, (numbers 7, 8, 11, and 12 from Figure 3(a)). N: indicates immunoprecipitation with nonspeciﬁc goat IgG documents antibody speciﬁcity.
(Figure 3(b), left panel, arrow). Immunoprecipitation with
GAPDH was used to conﬁrm that only biotinylated proteins
were present as indicated by the absence of SA-HRP reactive
bands (Figure 3(b),l a n eG ,l e f ta n dr i g h tp a n e l s ) .G o a tI g G
was used as a control of antibody speciﬁcity (Figure 3(b),
lane N).
Both CD74 and MIF immunoprecipitation reactions
showed a biotinylated (cell-surface) protein band at the
same molecular weight (76kDa), which could be attributed
to a cell-surface CD74-MIF complex that is not broken
upon reducing conditions (asterisk Figure 3(b)). Therefore,
co-immunoprecipitation of cell-surface proteins with MIF
antibody followed by CD74 Western blotting was used
to determine if CD74 was associated with immunopre-
cipitable biotinylated (cell-surface) MIF. In addition co-
immunoprecipitation was used to determine if SP treat-
ment increased the amount of this complex. SP treatment
increased the amount of this complex greater than twofold
(P = .02, Figure 3(c) saline lanes 1–4, animals 1, 2, 3, 6,
total intensity 32733 ± 17311 arbitrary units; SP lanes 1–4,
animals 7, 8, 11, 12, total intensity 13956 ± 2505 arbitrary
units). These results suggest that SP treatment increased
availability of cell-surface CD74 receptor for MIF binding.
Along with increased cell-surface CD74 and MIF SP-
treatment also resulted in increased gene expression of both
CD74 and MIF within isolated urothelial cells (Figure 4).
Finally, in order to conﬁrm that CD74 localizes to
the bladder urothelial cell surface and that cell-surface
expression is increased with SP treatment, nonpermeabilized
bladder tissue was immunostained using CD74 antibody
(SantaCruz,sc-5438)andexaminedbyconfocalmicroscopy.
CD74 antibody detected expression in a subpopulation of
these cells. As seen in Figure 5, CD74 protein expression
is localized to the cell surface and is increased with SP
treatment(Figures5(b),5(c)).Controlexperimentsincluded
tissue not exposed to secondary antibody (Figure 5(d)).
4. Discussion
MIF is a constitutively expressed, multifunctional cytokine
that functions to counterregulate the eﬀects of glucocorti-
coids and to stimulate the synthesis and secretion of other6 Mediators of Inﬂammation
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Figure 4: (a) MIF and CD74 mRNA expressions in isolated urothelial cells. Total RNA was isolated from urothelial cells and CD74 or
MIF-speciﬁc primers used to amplify mRNA by endpoint PCR. A CD74 and MIF mRNA is increased in isolated urothelial cells after SP
treatment. Data are representative of 5 salines and 5 SP-treated animals. 18S rRNA was used as a control for the amount of total RNA added
to each reaction tube. (b) Relative expression of CD74 and MIF in isolated urothelial cells. Data are expressed as fold change calculated by
determiningmean geneexpression ratio (netintensityof gene-speciﬁc band divided bynet intensityof 18SrRNAband)normalized tosaline
controls. (∗∗∗P<. 001, n = 5).
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Figure 5: CD74 confocal microscopy. Frozen bladder sections (14μm; intact bladders) were exposed to CD74 antiserum and visualized
using secondary antiserum labeled with FITC or TRITC. Control experiments included omission of the primary antiserum (panel D). (a)
Saline-treated bladder with 40× objective. (b) SP-treated bladder with 40× objective. (c) SP-treated bladder with 100× objective. (d) Saline-
treated bladder with 40× objective, secondary antibody only. Excitation wavelength of 488nm wasused and emission wavelength of 505nm
and up was collected. Frame size of the image for (a), (b), and (d) is 230.3μm × 230.3μm; optical thickness of the images is 2μm. Frame
size of the image for (c) is 92.1μm × 92.1μm; optical thickness of the image is 0.9μm. LP: lamina propria; NUC: nucleus; arrows indicate
luminal surface of urothelial cells.Mediators of Inﬂammation 7
proinﬂammatory mediators such as TNF-α and IL-1β,a s
such it has been suggested that MIF is a key initiator
of the inﬂammatory cascade [21, 22]. In addition to its
function in the inﬂammatory response, MIF functions as an
autocrine regulator of cell proliferation and diﬀerentiation.
Serum-starved NIH/3T3 cells secreted endogenous MIF as a
consequence of serum stimulation resulting in proliferation
of quiescent cells. This response was associated with phos-
phorylation and subsequent activation of ERK 1/2 [23].
SP is an aﬀerent nerve ﬁber neurotransmitter that medi-
ates inﬂammation by inducing vasodilatation and plasma
extravasation [24]. SP has a short half-life suggesting that
inﬂammation initially induced by SP is maintained by the
release of other proinﬂammatory mediators [24]. Our pre-
vious experiments established MIF as one such SP-induced
proinﬂammatory mediator [4]. SP aﬀects the rat bladder
by upregulating MIF expression and inducing the release
of urothelial MIF into the bladder lumen [4]. Sequestering
the MIF released into the bladder lumen with anti-MIF
antibodies decreases SP-induced inﬂammatory changes in
the bladder [8]. In addition, our studies have shown that
the MIF receptor, CD74, is also found in the urothelium
and that SP increases CD74 protein and mRNA amounts
in the bladder [15]. The ﬁndings of this study show that
this increase in MIF and CD74 mRNA is localized to
the urothelium. Thus, we propose that MIF, constitutively
expressed by the urothelium and upregulated in SP-induced
inﬂammation, binds to cell-surface CD74 receptor, which
perpetuates inﬂammation. Direct evidence of SP-induced
MIF-CD74 interaction had not been described previously.
The aim of the present experiments was to determine SP-
induced cell-surface CD74 expression and the interaction of
cell-surface CD74 with MIF in the rat urothelium.
It is diﬃcult to account for the absence of an MIF
response under “normal” physiological conditions consid-
ering the ubiquitous expression of this protein [25]. MIF
is readily detected in urine suggesting that bioactive MIF
is readily available in the local environment [2, 4]. CD74
amounts within the normal bladder are present in low
amounts and our previous immunoprecipitation studies
demonstrated increased MIF-CD74 complexes as a result of
SP-induced inﬂammation, suggesting that it is likely CD74
availability controls the cellular response to exogenous MIF
[15]. Interestingly, we found that CD74 expression in SP-
treated bladder is limited largely to the urothelial cell layer
surface, a diﬀerentiated cell type believed to play a role in
maintaining the integrity of the urothelium (Figure 5).
Under normal physiological conditions, urothelial cells
that do not express cell-surface CD74 (or express small
amounts of CD74) would not be able to respond to
secreted MIF via the well-described CD74-mediated ERK-
activation. The results presented here suggest that increased
cell-surface expression of CD74 induced by SP results in
greater binding of secreted MIF molecules by CD74, and
therefore greater activation of CD74-mediated signaling
pathways (e.g., ERK-activation). In particular, the results
of the immunoprecipitation experiments described here
establishthatSPtreatmentresultsinanincreasedcell-surface
CD74/MIF complex when compared with saline controls
(Figure 3(c)). Stable immunoprecipitable CD74 complexes
of similar molecular weights to what we report here have
been identiﬁed previously in both human peripheral blood
T-cells and duodenal epithelial cells [26, 27]. The exact
nature and function of these complexes was not established.
In their entirety, these results suggest that the relative
contributions of MIF to normal bladder function are min-
imal, but inﬂammatory processes are reliant upon bioactive
MIF and cell-surface expression of the MIF receptor, CD74.
This would imply that pharmacologic inhibition of MIF
(e.g., using pharmacological antagonists of MIF tautomerase
activity with ISO-1) would have little eﬀect on normal
bladder function, but may prove to be a potent bladder
inﬂammatory inhibitor. As evidenced by the data presented
here, a model for MIF response at the cellular level emerges:
under normal conditions although MIF is present in the
surrounding tissues as well as in the peripheral blood; the
cell-surface receptor is absent. In response to inﬂammatory
stimuli, epithelial cells express the MIF receptor (CD74) on
their surface, thus initiating inﬂammatory response.
5. Conclusions
In summary, the present study documents increased MIF
and urothelial cell-surface CD74 expression during inﬂam-
mation. The emerging role of MIF in bladder inﬂammation
suggests that modulating this cytokine activity may result in
new, selective, and therapeutic modalities.
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